


med onc, interested in trial design, endpoints and scientifically rigorous measurement of the patient experience- tweets and opinions are my own


nejm.org/doi/full/10.1056/NE… A shout out to Drs.Mirat Shah and Atik Rahman for Project Optimus!

Please join if you can. Patient generated data to inform the tolerability of drug products… exploring single item overall side effect impact with some fantastic experts in the #PRO field
This tweet is unavailable

This session did a nice job hearing both sides of the story on early endpoints and accelerated approval in oncology. Kudos to @FDAOncology Angelo De Claro for his balanced perspective.
This tweet is unavailable

Open access article in @TheCancerLetter worth reading. Discusses @FDAOncology Rick Pazdur's perspective on the oncology #drugshortage
This tweet is unavailable

The ORISE fellowship program has been such a productive opportunity for early career scientists to work with FDA on applied research questions @FDAOncology @Meena_PharmD
This tweet is unavailable

Excited to kick off this year's great line up of @FDAOncology regulatory science sessions by moderating an #AACR23 panel on #DecentralizedTrials for #Oncology #ClinicalResearch. Looking forward to seeing everyone in Orlando! Session details here https://t.co/psHTMeONhj
Adaptations to the #COVID19 pandemic showed that decentralized oncology trials are feasible. On Sunday, April 16, @FDAOncology Deputy Director Paul Kluetz will moderate a panel discussion on how to make these changes permanent at #AACR23. https://t.co/ApHCIefJTn

Incredibly excited to share a very informative #FDA guidance on #externalcontrols hot off the presses! So proud to have led the #statistics effort on this one, in conjunction with colleagues across @US_FDA including @FDAOncology fda.gov/regulatory-informati…

@GitaThanaMD presenting the In4M study during the digital technology scientific workshop. Solutions to study challenges include modified eligibility criteria and patient outreach to help with wearable devices issues. #ASH22 @cpgYALE @pkluetz

It was a wonderful experience to share my pt perspectives & learn at the @US_FDA Project FrontRunner Mini Symposium yesterday 👆explored moving #clinicaltrials with novel agents to earlier lines in St IV #CRC Lots of insightful discussions 👀forward to more new drugs for more pts


Thankful to be @ASCO faculty for the 1st time at #ASCO22 with these incredible panelists ➡️ @DrEdKim @jillfeldman4 @LundJenny discussing methods to enhance patient centric clinical evidence generation across the continuum. #RCT #RWD Please join the discussion on June 5th!
#ASCO22 Education Session to focus on the role of real-world data in improving #clinicaltrials 📊💻 fal.cn/3oYTG #ASCODailyNews @DrEdKim @cityofhope @DrDonnaRivera @FDAOncology @LundJenny @uncpublichealth @jillfeldman4 @EGFRResisters #RWE

🐊Really honored to be a #40GatorsUnder40! 🧡💙Abundant gratitude to my family, friends, & colleagues for your guidance and collaboration! 🧡💙 Thanks @ufalumni @UFPharmacy. Dream Big, Build Resilience, & Be Kind! Go out there and change the 🌎 #GoGators #GoGreater @FDAOncology
Congratulations to @DrDonnaRivera, associate director for pharmacoepidemiology in the Oncology Center of Excellence at the @US_FDA for being named to #40GatorsUnder40 class of 2022! She is a '12 PharmD and '14 MS graduate of @UFPharmacy. @DCGatorClub #GatorNation #GoGators

Impactful use of #PRO and other patient generated data-> treatment side effects and impacts -> tolerability -> optimizing dose. #projectoptimus #OCEPFDD @vishalbmd #AACR22 #fdaoncology
This tweet is unavailable

#BLOODPACSummit @FDAOncology @DrJuliaBeaver I have seen the impact of #BLOODPAC from a clinical standpoint, it has allowed for trial initiation and clinical data getting generated.

FDA pushes cancer trials to include more elderly people | Science | AAAS science.org/content/article/…